Ronald M Bukowski MDEmeritus Staff PhysicianCleveland Clinic Taussig Cancer CenterProfessor Emeritus of MedicineCCF Lerner College of Medicine of CWRURobert Figlin MDProfessor of Medicine and Biomedical SciencesDirector, Division of Hematology OncologyDepartment of Medicine, Cedars-Sinai Medical CenterAssociate Director for Academic ProgramsSamuel Oschin Comprehensive Cancer InstituteProfessor Emeritus of Medicine and UrologyDavid Geffen School of Medicine at UCLARobert Motzer MDAttending PhysicianDepartment of MedicineMemorial Sloan-Kettering Cancer CenterProfessor of MedicineWeil Medical College of Cornell University

From the book reviews: "This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field." (Jianqing Lin, Doody's Book Reviews, February, 2015)

• Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 2: RCC: Pathologic and Molecular assessment of Targets; Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications; Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex; Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes; 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?; Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results;  9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status; Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?; Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC; Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC; Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma; Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma; Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma; Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance; Ch. 17: Development of Combination Therapy with Targeted Agents; Ch. 18: Side Effects ofTargeted Thearpy; Ch. 19: The Role of Targeted Therapy in Special Populations; Ch. 20: Immunotherapy: the Current Role of Cytokines; Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC; Ch. 22: Vaccines in RCC: Clinical and Biological Relevance; Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics; Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma; Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma; Ch. 26: The Role of Advocacy in Renal Cell Carcinoma

Ronald M Bukowski MDEmeritus Staff PhysicianCleveland Clinic Taussig Cancer CenterProfessor Emeritus of MedicineCCF Lerner College of Medicine of CWRURobert Figlin MDProfessor of Medicine and Biomedical SciencesDirector, Division of Hematology OncologyDepartment of Medicine, Cedars-Sinai Medical CenterAssociate Director for Academic ProgramsSamuel Oschin Comprehensive Cancer InstituteProfessor Emeritus of Medicine and UrologyDavid Geffen School of Medicine at UCLARobert Motzer MDAttending PhysicianDepartment of MedicineMemorial Sloan-Kettering Cancer CenterProfessor of MedicineWeil Medical College of Cornell University

From the book reviews: "This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field." (Jianqing Lin, Doody's Book Reviews, February, 2015)

• Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 2: RCC: Pathologic and Molecular assessment of Targets; Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications; Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex; Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes; 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?; Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results;  9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status; Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?; Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC; Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC; Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma; Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma; Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma; Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance; Ch. 17: Development of Combination Therapy with Targeted Agents; Ch. 18: Side Effects ofTargeted Thearpy; Ch. 19: The Role of Targeted Therapy in Special Populations; Ch. 20: Immunotherapy: the Current Role of Cytokines; Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC; Ch. 22: Vaccines in RCC: Clinical and Biological Relevance; Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics; Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma; Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma; Ch. 26: The Role of Advocacy in Renal Cell Carcinoma

Ronald M Bukowski MDEmeritus Staff PhysicianCleveland Clinic Taussig Cancer CenterProfessor Emeritus of MedicineCCF Lerner College of Medicine of CWRURobert Figlin MDProfessor of Medicine and Biomedical SciencesDirector, Division of Hematology OncologyDepartment of Medicine, Cedars-Sinai Medical CenterAssociate Director for Academic ProgramsSamuel Oschin Comprehensive Cancer InstituteProfessor Emeritus of Medicine and UrologyDavid Geffen School of Medicine at UCLARobert Motzer MDAttending PhysicianDepartment of MedicineMemorial Sloan-Kettering Cancer CenterProfessor of MedicineWeil Medical College of Cornell University

From the book reviews: "This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field." (Jianqing Lin, Doody's Book Reviews, February, 2015)

• Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 2: RCC: Pathologic and Molecular assessment of Targets; Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications; Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex; Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes; 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?; Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results;  9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status; Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?; Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC; Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC; Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma; Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma; Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma; Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance; Ch. 17: Development of Combination Therapy with Targeted Agents; Ch. 18: Side Effects ofTargeted Thearpy; Ch. 19: The Role of Targeted Therapy in Special Populations; Ch. 20: Immunotherapy: the Current Role of Cytokines; Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC; Ch. 22: Vaccines in RCC: Clinical and Biological Relevance; Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics; Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma; Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma; Ch. 26: The Role of Advocacy in Renal Cell Carcinoma